SOUTH SAN FRANCISCO, Calif., Oct. 5 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. (NGM), a privately held biotechnology company dedicated to the discovery and development of novel biotherapeutics for the treatment of Type 2 diabetes and other metabolic diseases, announced today that William J. Rieflin has been named Chief Executive Officer and appointed to NGM's Board of Directors.
"We are delighted that Bill will be leading NGM in the next phase of its evolution," said David V. Goeddel, Ph.D., NGM's Chairman. "Bill's experience building innovative companies is the perfect match for NGM's exceptional team and promising technology."
Mr. Rieflin brings over 20 years of industry experience to NGM. Most recently, he was President of XenoPort, Inc. and currently serves on XenoPort's Board of Directors. Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik, Inc., which was acquired by Amgen, Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.
"I am pleased to join the NGM team, which has already made significant progress in its quest to discover differentiated, clinically important medicines," said Mr. Rieflin. "With groundbreaking discoveries increasingly shifting to smaller, entrepreneurial companies, I am excited by the prospect of leading a team with a great chance of discovering the next generation of novel therapies to treat the unmet needs of patients with metabolic diseases."
About NGM Biopharmaceuticals
NGM Biopharmaceuticals, Inc. is a privately held drug discovery and development company dedicated to developing transformational medicines that significantly improve human health. NGM has devised a novel discovery platform, relying on human clinical and genetic observations, to identify and validate targets that impact the underlying etiology of disease. The Company's strategy is to focus on mining the complex biological interactions within the neuroendocrine gastrointestinal environment to elucidate the roles of previously unidentified or unexplored hormones, receptors and other metabolic factors that are involved in the systemic regulation of glucose homeostasis and that play causative roles in diseases.
NGM is generating a rich pipeline of new targets that the Company is using to develop novel treatments for metabolic diseases, such as obesity, muscle wasting and cardiovascular disease in addition to diabetes. Founded in 2008, NGM has world-class scientists and an accomplished executive team with broad experience in building and managing biotechnology companies. NGM is headquartered in South San Francisco, California. For more information, please visit the Company's website at http://www.ngmbio.com.
SOURCE NGM Biopharmaceuticals, Inc.